PDT Partners LLC Has $730,000 Stock Holdings in Pulmonx Co. (NASDAQ:LUNG)

PDT Partners LLC lifted its holdings in Pulmonx Co. (NASDAQ:LUNG) by 25.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,074 shares of the company’s stock after acquiring an additional 17,784 shares during the quarter. PDT Partners LLC’s holdings in Pulmonx were worth $730,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. nVerses Capital LLC bought a new stake in Pulmonx during the 3rd quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Pulmonx during the second quarter worth approximately $37,000. SG Americas Securities LLC bought a new stake in shares of Pulmonx during the third quarter valued at approximately $102,000. Hsbc Holdings PLC acquired a new stake in shares of Pulmonx in the second quarter valued at approximately $93,000. Finally, Mackenzie Financial Corp bought a new position in Pulmonx in the 2nd quarter worth approximately $102,000. 91.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lowered their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

Insider Buying and Selling

In related news, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the sale, the director now owns 1,091,974 shares of the company’s stock, valued at approximately $7,119,670.48. This trade represents a 1.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 60,000 shares of company stock worth $424,800 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Pulmonx Stock Up 1.2 %

Shares of NASDAQ LUNG opened at $6.53 on Tuesday. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $14.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The stock has a market cap of $257.86 million, a P/E ratio of -4.44 and a beta of 0.68. The firm has a 50 day moving average price of $6.87 and a 200 day moving average price of $7.03.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. The firm had revenue of $20.39 million during the quarter, compared to analysts’ expectations of $20.39 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. Analysts expect that Pulmonx Co. will post -1.53 EPS for the current year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.